- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
AMCP: Reduce readmissions with MTM
A partnership between Catamaran and Health New England achieved a 30% reduction in 30-day readmissions, presented at Session 216 at AMCP
When payers and pharmacy benefits managers collaborate on medication therapy management (MTM), they can drive positive impact on readmission rates.
A partnership between Catamaran and Health New England, a managed care organization in Springfield, Mass., achieved a 30% reduction in 30-day readmissions, according to panelist David Calabrese, vice president and chief pharmacy officer for Catamaran, who will be presenting at Session 216 today.
“Medical errors and non-adherence are two of the primary causes driving readmissions and costly hospital stays,” Calabrese says. “Pharmacists are the most important people to intervene and ensure that patients are filling their prescriptions on time, avoiding duplications and managing side effects and interactions because they have the most direct contact with patients.”
He says multidisciplinary protocols ensure that members are engaged while active monitoring drives improved care-plan adherence.
By combining analytics, technology, clinical expertise, post-discharge medication reconciliation and counseling, comprehensive medication review and medication adherence, MTM programs ensure that patients with a variety of conditions understand their medications post-discharge avoiding confusion with their regimens prior to hospital admission. Industry insights and preliminary results of the program will be presented in today’s case study session.
In June 2007, MedPAC documented that nearly 20% of all Medicare admissions result in readmissions within 30 days of discharge, accounting for $15 billion in spending, of which about $12 billion is for potentially preventable readmissions.
According to CMS, more than 2,200 hospitals were penalized an aggregate of about $280 million in Medicare payments because of their excess readmissions in 2012, with an estimate of $227 million in 2013.
In addition, all-cause readmission rates are part of Medicare’s star rating program measurements under Part C. The average rating for the metric dropped slightly in 2013 when compared to 2012.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
